Document Detail


Bromocriptine in the long-term management of advanced Parkinson's disease.
MedLine Citation:
PMID:  6861013     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thirty-seven patients with advanced Parkinson's disease who initially tolerated, and responded to bromocriptine therapy were followed for 12 to 50 (mean 28) months. Using a method of gradual increase of bromocriptine, with concomitant levodopa reduction, the peak effect of the drug was apparent by three months, at which time the mean daily dose of bromocriptine was 23.9 mg and Sinemet (levodopa + carbidopa) had been reduced by 34 percent. Eight patients had sustained improvement without further drug changes for an average of 29 (range 14-50) months. After periods of improvement varying between 3 and 30 months, 29 patients had a fall-off from peak effect. Peak effect was regained in 21 of these 29 patients for an average of 16 additional months by initially increasing bromocriptine or Sinemet, or by eventually increasing both drugs. The main adverse effect was a confusional state which necessitated late withdrawal of bromocriptine in four patients. The best results were in younger patients with end-of-dose deterioration and levodopa induced dyskinesias. With cautious introduction, and intermittent dosage adjustment, bromocriptine can be of long-term benefit to patients with advance Parkinson's disease. The majority of patients have a gradual late fall-off in effect which can frequently be reversed with dosage adjustment.
Authors:
J D Grimes; M N Hassan
Related Documents :
21351883 - Novel surgical technique for obstructive benign prostatic hyperplasia: finger-assisted,...
21184513 - Gait after unilateral total knee arthroplasty: frontal plane analysis.
7414463 - Principles of operation for combined aortoiliac and femoropopliteal occlusive lesions.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques     Volume:  10     ISSN:  0317-1671     ISO Abbreviation:  Can J Neurol Sci     Publication Date:  1983 May 
Date Detail:
Created Date:  1983-08-26     Completed Date:  1983-08-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0415227     Medline TA:  Can J Neurol Sci     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  86-90     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Bromocriptine / adverse effects,  therapeutic use*
Drug Evaluation
Follow-Up Studies
Humans
Parkinson Disease / drug therapy*,  physiopathology
Time Factors
Chemical
Reg. No./Substance:
25614-03-3/Bromocriptine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hemispherectomy for seizures revisited.
Next Document:  Epilepsy from cerebral arteriovenous malformations.